Sanofi SA SNYNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
EU Accepts Sanofi's Concessions to End Antitrust Probe Over Vaccine Marketing — Update
-
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
-
Flu season is already here. Here's what to know about this year's flu shots.
-
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
-
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
-
European Pharma Leaders Push for National Reforms to Boost Investment
-
Sanofi to Take Stake in Cheplapharm in Swap for Drug Portfolio, Manufacturing Sites
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
Trading Information
- Previous Close Price
- $78.55
- Day Range
- $78.48–78.48
- 52-Week Range
- $76.76–106.34
- Bid/Ask
- $49.59 / $127.47
- Shares Outstanding
- 1.20B
- Market Cap
- $94.01B
- Volume/Avg
- 450 / 18,554
Key Statistics
- Price/Earnings (Normalized)
- 11.15
- Price/Sales
- 1.67
- Dividend Yield (Trailing)
- 6.17%
- Dividend Yield (Forward)
- 6.17%
- Dividend Payment Schedule
- May
- Total Yield
- 11.90%
Company Profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 74,846
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SNYNF
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.15 | 14.45 | 44.74 |
Price/Book Value | 1.30 | 6.87 | 8.46 |
Price/Sales | 1.67 | 5.11 | 5.35 |
Price/Cash Flow | 6.89 | 15.08 | 16.08 |
Price/Earnings
SNYNF
NVS
MRK
Financial Strength
|
Metric
|
SNYNF
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.55 | 0.71 |
Current Ratio | 0.99 | 0.86 | 1.32 |
Interest Coverage | 8.05 | 11.90 | 4.28 |
Quick Ratio
SNYNF
NVS
MRK
Profitability
|
Metric
|
SNYNF
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 7.96% | 14.74% | 6.27% |
Return on Equity (Normalized) | 14.96% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 11.28% | 21.25% | 9.82% |
Return on Assets
SNYNF
NVS
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|%>b?SqK! | LOCK|>T> | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|w?&<H@! | LOCK|$$b | $612B | |||
| AbbVie Inc
ABBV
| LOCK|&BMkDX | LOCK|s$Q | $500B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@w@r@$w | LOCK|^m | $368B | |||
| Merck & Co Inc
MRK
| LOCK|Q$&R?<K | LOCK|?h | $354B | |||
| Novartis AG ADR
NVS
| LOCK|XThjm#w | LOCK|GV | $287B | |||
| AstraZeneca PLC
AZN
| LOCK|qbz>Z$&c | LOCK|!g | $256B | |||
| Amgen Inc
AMGN
| LOCK|yJt#l$LP | LOCK|mvb | $230B | |||
| Gilead Sciences Inc
GILD
| LOCK|hK?Jks | LOCK|Fql | $190B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Lr^gnn | LOCK|%cz | $170B |
United States